Patients with newly diagnosed type 2 diabetes can benefit from early insulin therapy to lower cardiovascular event risks, contrasting with current practices that prioritize lifestyle changes first.
Summary: Early insulin therapy significantly reduces cardiovascular events in newly diagnosed type 2 diabetes patients, according to research published in Signal Transduction and Targeted Therapy. Observing 5,424 patients over 24 years, the study found that early insulin use led to a 31% reduction in stroke and 28% decrease in heart failure hospitalizations compared to those who delayed insulin therapy. This challenges the traditional step-by-step approach, suggesting a need to reconsider early insulin adoption for better cardiovascular outcomes.
Key Takeaways:
- Significant Reductions: Early insulin therapy reduces the incidence of stroke by 31% and heart failure hospitalizations by 28% in newly diagnosed type 2 diabetes patients.
- Treatment Approach: The findings challenge the traditional gradual intensification strategy, advocating for early insulin adoption to improve cardiovascular health outcomes.
- Clinical Implications: The study suggests rethinking current treatment protocols, emphasizing the importance of early insulin therapy in managing type 2 diabetes to reduce cardiovascular risks.
Early insulin therapy is associated with a significant reduction in the incidence of cardiovascular events in newly diagnosed patients with type 2 diabetes mellitus, according to research published in Signal Transduction and Targeted Therapy.
Diabetes has remained a serious global public health issue for over a century, with its burden growing as populations shift to more urban, sedentary ways of living. The heightened blood glucose levels of a person with diabetes can damage their cardiovascular systems, placing them at increased risk of cardiovascular events, which is why cardiovascular disease is one of the leading causes of mortality among people with diabetes.
As such, effective blood glucose control, which has always been the main goal of diabetes therapy, is important to reduce the risk of cardiovascular events.
For the study, researchers observed 5,424 patients with type 2 diabetes over 24 years. The results showed that, compared with patients who did not receive early insulin therapy, those who did saw a 31% reduced incidence of stroke and 28% reduction in hospitalization for heart failure, though it found no significant difference in the risk of coronary heart disease.
Researchers say this discovery stands to change the way doctors and patients approach therapy options for new diagnoses of TD2M, as the significant cardiovascular benefits may lead more favoring early insulin adoption at a time when many first explore alternatives to insulin therapy.
Decades of Research into Early Insulin Therapy
The traditional model for treating newly diagnosed type 2 diabetes mellitus is a conservative “step-by-step” method that typically begins with lifestyle changes such as diet and exercise, with physicians only recommending pharmaceutical intervention such as insulin once the disease has progressed and it is becoming clear that blood glucose levels are going uncontrolled.
This can be a problematic approach, according to study author Jianping Weng of the University of Science and Technology of China and president of Anhui Medical University, as this often means that patients go months, even years, with high blood glucose levels causing lasting internal damage and increasing risk of complications.
After years of clinical experience struggling with this contradiction, in 2000, Chinese endocrinologists Weng and Linong Ji, MD, director of endocrinology and metabolism at Peking University People’s Hospital and co-author of the current study, began formally exploring the effects of early insulin therapy on patient outcomes. Initial results proved promising, as early insulin therapy demonstrated an improvement in pancreatic islet secretion and reduced complications from diabetes.
This study proved that, with the right therapy, type 2 diabetes mellitus could be reversed and thus became an important basis for the formulation of diabetes guidelines in many countries.
In 2001, Weng and Ji also coincidentally discovered that insulin intensification in type 2 diabetes can delay the progressive failure of beta cells. Subsequent observational studies by Weng’s team showed that short-term intensive insulin treatment in patients with newly diagnosed T2DM and people with severe hyperglycemia could induce long-term improvements in blood glucose control and beta cell function. These research results were published in Diabetes Care in 2004.
Weng’s team then conducted a multi-center randomized controlled study demonstrating that early insulin therapy was superior to oral blood glucose drugs in restoring and maintaining beta cell function and lowering overall blood glucose levels. These results were published in The Lancet in 2008, marking the first time such a “honeymoon period” induced by early insulin therapy was mentioned in the prestigious publication.
Weng and his team proved that pancreatic islet function in type 2 diabetes mellitus is reversible and successfully verified the “beta cell rest” theory in type 2 diabetes mellitus therapy.
“Clinical results show that early insulin therapy can not only successfully control blood glucose and reduce overall blood sugar levels, but also restore beta cell function and reduce insulin resistance,” says Weng in a release. “This new treatment method encourages us to rethink how we approach diabetes treatment and significantly impact how we formulate treatment strategies.”
Initially proposed to answer the question as to when physicians should recommend starting insulin treatment, Weng’s research is still often cited by endocrinologists.
Cardiovascular Benefits of Early Insulin Therapy
For most people with type 2 diabetes mellitus, insulin therapy is eventually necessary in order to control blood glucose levels. Previous studies demonstrated that early insulin therapy can help control blood sugar and restore beta cell function in patients with type 2 diabetes, but how this therapy affected cardiovascular health has remained a mystery.
This recently published study into how early insulin therapy can reduce the incidence of cardiovascular events such as stroke, heart failure, and coronary heart disease in newly diagnosed patients with type 2 diabetes mellitus can be seen as a follow-up to Weng’s 2008 article in The Lancet in that it demonstrates even further benefits from early insulin therapy on long-term patient outcomes.
This new evidence promoting early insulin therapy could change the future of insulin therapy and provide key evidence for setting treatment guidelines, according to the reserachers.
Speaking on the results of this study, Ji says in a release, “Type 2 diabetes is an important risk factor for cardiovascular disease morbidity and mortality. Clinical guidelines also emphasize that, when selecting a potential therapy, in addition to lowering blood glucose levels, it is also very important to reduce the risk of cardiovascular events. Different patients should adopt individualized target management, blood sugar monitoring, and corresponding treatment plans. We hope that this study will provide a basis for exploring more effective ways to reduce the risk of cardiovascular disease in patients with diabetes.”
Early insulin therapy may bring cardiovascular benefits by improving blood glucose control in patients with type 2 diabetes, producing metabolic memory, reducing glucotoxicity, promoting the dedifferentiation of beta cells, improving beta cell function, and reducing the production of pro-inflammatory cytokines.
Photo 60110503 © Syda Productions | Dreamstime.com
